Citations

Clear

14 citation(s) found for "Schnitt, S J".

Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.
Deshmukh, Sachin Kumar, Fanucci, K., Oesterreich, Steffi, Wu, Sharon, Xiu, Joanne, Advani, Pooja , Coelho, P. Barreto, Schnitt, S J, Lin, Nancy, Tolaney, Sara M., Metzger, Otto, Sledge, George W., Jeselsohn, Rinath, Marta, Guilherme Nader , Deshmukh, Sachin Kumar , Lee, Adrian V. , Oesterreich, Steffi , Wu, Sharon , Xiu, Joanne , Coelho, Priscila Barreto, Lustberg, Maryam B. , Tolaney, Sara M. , Mayer, Erica L. , Metzger, Otto , Jeselsohn, Rinath

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1024-1024

10.1200/jco.2026.44.16_suppl.1024 Get It

1024 Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer (BC) subtype with dissemination patterns differing from invasive breast carcinoma of no special type (IBC-NST). While genomic differences between ILC and IBC-NST have been described, the extent to which molecular and immune profiles vary by metastatic organ and histology is poorly characterized. Methods: We conducted a retrospective analysis to evaluate organ- and histology-specific molecular features of metastatic BC (mBC). Patients with metastatic IBC-NST or pure ILC underwent NGS (592, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Tumor mutational burden (high ≥10 mut/Mb), PD-L1 expression (22C3), and immune cell fractions (RNAseq deconvolution, quanTIseq) were assessed. Analyses were restricted to sites with ≥10 biopsies per histology. Comparisons used chi-square or Mann–Whitney U tests with multiple testing correction (q < 0.05). Results: A total of 2645 mBC biopsies (605 ILC; 2040 IBC-NST) were analyzed (Table). In ILC, ERBB2 mut frequency differed by metastatic site (q<0.01), with higher prevalence in liver (32.7%) and lower in gastrointestinal (GI) lesions (3.7%). In IBC-NST, ESR1 and GATA3 mut and FGFR1 amplification were enriched in liver metastases, whereas PD-L1 expression was highest in skin (20.7%) and lowest in liver (5.0%). No organ-specific differences were observed for PIK3CA, AKT, PTEN, BRCA1/2 or RB1 . Across metastatic sites, both ILC and IBC-NST showed differences in B cells, macrophages (M1/M2), neutrophils, NK cells, dendritic cells, CD8+ T cells, and Tregs (all q < 0.05); CD4+ T-cell differences were observed only in IBC-NST (q = 0.002). In organ-specific ILC vs IBC-NST comparisons, CDH1 mut were more frequent in ILC across sites, along with higher PIK3CA mut in skin (ILC 51.3% vs IBC-NST 34.4%) and higher ERBB2 mut in liver (32.7% vs 3.3%), whereas a higher TP53 mut frequency was observed in IBC-NST in skin (28.5% vs 52.3%) and lymph nodes (LND) (23.5% vs 55.5%) (all q < 0.01). Conclusions: mBC exhibits marked organ-specific molecular and immune heterogeneity that differs by histology. These findings support histology- and site-aware interpretation of metastatic biopsies and may inform biomarker assessment and treatment decisions in advanced disease. BC-NST ILC Skin LND Bone Breast Liver Perit. CNS q-value Skin LND Bone Breast GI Liver GYN Perit. CNS q-value N (specimens) 785 401 109 361 220 15 44 - 172 84 62 56 56 54 43 37 11 - ERBB2 mut (%) 3.2 3.1 3.2 2.3 3.3 7.1 2.5 1.0 7.1 7.4 16.4 15.4 3.7 32.7 2.4 5.7 11.1 <0.01 ESR1 mut (%) 9.4 5.2 8.3 16.0 28.2 7.1 2.4 0.0 7.8 7.2 8.9 9.8 16.7 26.0 4.9 20.0 0.0 0.9 FGFR1 amp (%) 10.1 6.6 5.6 12.8 16.5 0.0 9.7 0.02 4.4 3.4 6.7 6.1 2.4 5.6 7.7 18.5 0.0 1.0 IHC-PD-L1 (%) 20.7 - 5.3 16.0 5.0 11.1 10.3 0.02 8.9 - 5.0 5.7 6.1 0.0 0.0 0.0 14.3 1.0 TMB-High (%) 10.7 10.1 8.8 8.8 8.5 14.3 21.4 0.8 27.6 11.0 19.6 28.0 11.3 19.6 9.8 32.4 22.2 0.8 Perit: peritoneum; CNS: central nervous system; GYN: genital tract.
World Health Organization classification of tumours of the breast 6th edition 2026
Quinn, Cecily , Tan, Puay Hoon , Allison, Kimberly H. , Brogi, Edi , Lakhani, Sunil R. , Schnitt, Stuart J. , Fox, Stephen B. , Jaffer, Shabnam , Şahin, Ayşegül A. , Salgado, Roberto , Adjei, E, Helbich, Thomas H. , Sotiriou, C, Hodge, Jennelle C. , Khoury, Joseph D. , Puspanathan, Pavitratha, Giesen, Christine, Ruiz, Blanca Iciar Indave , Ellis, Ian, Lokuhetty, Dilani , Board, WCT Standing Editorial, Netto, George J. , Sahin, Aysegul , Sapino, Anna , Adjei, Ernest Kwasi , Geiersbach, Katherine , Helbich, Thomas H , Lambertini, Matteo , Sotiriou, Christos P. , Hodge, Jennelle C , Khoury, Joseph , Rekhi, Bharat , Ryska, Ales , Tse, Gary , Field, Andrew , Wijesinghe, Harshima , Puspanathan, Pavitratha , Giesen, Christine , Ruiz, Blanca Iciar Indave , Ellis, Ian , Lokuhetty, Dilani , Geiersbach, Katherine B. , Lambertini, Matteo , Field, Andrew , Ellis, Ian O. , board, WCT standing editorial

Mayo Clinic

Histopathology | April 21, 2026 | Volume: 89 | Issue: 2 | Pages: 199-218

10.1111/his.70149 | PMID 42011085 Get It

The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.
Abstract 7903: MiR-362-3p enhances platinum response in breast cancer
Liu, Zhaoji, Ke, Shizhong, Li, Xiaohui, Wu, C., Uyemura, Madison M., Sardella, Barbara, Massicott, Erica S., Wang, Lin, Aronson, Emily K., Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, J. E., Schnitt, Stuart J. , Tung, Nadine M., Wulf, G. M., Heng, Yujing J., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Aronson, Emily K., Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Cheng, He, Munson, Phillip B. , Mayer, Erica L. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M. , Heng, Yujing J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7903-7903

10.1158/1538-7445.am2026-7903 Get It

Abstract The INFORM trial (NCT01670500) was a randomized, two-arm Phase II neoadjuvant study comparing the efficacy of a platinum-based regimen (cisplatin) versus an anthracycline (AC)-based regimen in participants with germline BRCA1/2 mutations and early-stage, HER2-negative breast cancer. MicroRNAs (miRNAs) are emerging as promising non-invasive biomarkers for disease detection and treatment monitoring. The initial aim of this study was to evaluate whether pretreatment plasma miRNA profiles were associated with treatment outcomes in the INFORM trial cohort. Pretreatment plasma samples from 97 INFORM participants (n=53 cisplatin and n=44 AC) were screened for 352 miRNAs commonly implicated in cancer using the qPCR-based ID3EALTM Cancer Panel. Twenty out of 53 participants achieved residual cancer burden (RCB) score of 0 or 1 with cisplatin and 20/44 with AC. Higher plasma miR-362-3p expression was associated with a favorable response to cisplatin (1.7-fold; p&lt;0.01), but not to AC. MiR-362-3p expression in paired pretreatment tumor biopsies (n=79) did not significantly correlate with plasma expression and was not associated with RCB 0/1 (p&gt;0.05). In TCGA, miR-362-3p expression was higher in breast tumors than in adjacent normal tissue, and higher in triple negative breast cancers (TNBCs) compared with hormone receptor-positive tumors (both FDR&lt;0.001), independent of BRCA mutation or Single Base Substitution Signature 3 (SBS3) status. The miR-362-3p findings in INFORM did not replicate in a sister trial, TBCRC 030 (NCT01982448; 11 out of 46 cisplatin-treated patients achieved RCB 0/1, p=0.46). These results suggest that while miR-362-3p is unsuitable as a circulating biomarker for cisplatin response, it may play an important biological role in mediating cisplatin sensitivity in TNBCs, independent of BRCA1/2 mutations. Functional studies demonstrated that miR-362-3p is expressed and secreted by TNBC cell lines, operates as a tumor suppressor, and generally correlates with cisplatin sensitivity. Overexpression of miR-362-3p rendered MDA-MB-231 and CAL-51 cells cisplatin sensitive, while knockdown induced resistance in MDA-MB-436 cells. Ongoing studies are testing whether these effects translate in xenograft models. In silico and functional assays identified BCLAF1, a DNA damage response (DDR) regulator, as a direct target of miR-362-3p. Overexpression of miR-362-3p suppresses BCLAF1 mRNA and protein levels. Our findings demonstrate that miR-362-3p enhances cisplatin responsiveness by targeting BCLAF1. A miR-362-3p-based therapeutic may be useful as a co-agent to enhance tumor responses to platinum-based chemotherapy. Citation Format: Zhaoji Liu, Shizhong Ke, Xiaohui Li, Catherine Wu, Madison M. Uyemura, Brian R. Sardella, Erica S. Massicott, Lin Wang, Emily K. Aronson, Dimitra Karagkouni, Nikolas Kalavros, Ioannis S. Vlachos, Felipe Batalini, Cristina S. Bogsan, Jit Kong Cheong, Lihan Zhou, He Cheng, Phillip Munson, Erica L. Mayer, Judy E. Garber, Stuart J. Schnitt, Nadine M. Tung, Andrea L. Kasinski, Frank J. Slack, Gerburg M. Wulf, Yujing J. Heng. MiR-362-3p enhances platinum response in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7903.
The miR-362-3p/ BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
Liu, Zhaoji, Wu, Catherine, Uyemura, Madison M., Sardella, Barbara, Aronson, Emily K, Ke, Shizhong, Massicott, Erica S., Li, Xiaohui, Wang, Lin, Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, Judy E, Schnitt, Stuart J. , Tung, Nadine M, Heng, Yujing J., Heng, Yujing J. , Wu, C., Aronson, Emily K., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Munson, Phillip B. , Mayer, Erica L. , Garber, Judy E. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M.

Mayo Clinic

No container title available | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.09.26347941 Get It

Abstract Platinum-based chemotherapy remains a cornerstone of treatment for triple-negative breast cancer (TNBC), yet the molecular determinants governing platinum response remain poorly defined. By leveraging the randomized Phase II INFORM trial, which compared neoadjuvant cisplatin to anthracycline-based therapy in BRCA1/2 -mutant breast cancer—we identified miR-362-3p as a specific regulator of cisplatin sensitivity. Higher plasma miR-362-3p expression was exclusively associated with favorable clinical outcome in the cisplatin arm, with no association observed in the AC arm, decoupling platinum-specific vulnerability from general chemotherapy response. We used gain- and loss-of-function TNBC models to establish that miR-362-3p functions as a potent sensitizer to cisplatin in vitro and in vivo . Integrated TCGA analysis and experimental validation identified BCLAF1, a key regulator of DNA damage response, as a direct repression target of miR-362-3p. We uncovered a novel role for the miR-362-3p/ BCLAF1 axis in overcoming platinum resistance in TNBC.
Abstract PD9-07: The Genomic, Transcriptomic, and Immune Hallmarks of Metastatic Lobular Breast Cancer
Nader-Marta, G., Deshmukh, S. Kumar, Fanucci, K., Schnitt, S., Lee, A. V., Oesterreich, S., Wu, S. K., Xiu, Joanne , Advani, Pooja , Lin, N. U., Tolaney, S. M., Mayer, E. L., Metzger, Otto, Sledge, G. W., Jeselsohn, R. M., Marta, Guilherme Nader , Tarantino, Paolo , Oesterreich, S., Wu, S., Lustberg, Maryam B. , Tolaney, Sara M. , Jeselsohn, Rinath

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD9-07-PD9-07

10.1158/1557-3265.sabcs25-pd9-07 Get It

Abstract Background: Invasive lobular carcinoma (ILC) is the second most common breast cancer (BC) subtype, accounting for up to 15% of cases. Although several biologic differences between ILC and invasive carcinoma of no special type (NST) have been described, most data are derived from primary tumors. In contrast, the biology of metastatic ILC remains poorly defined. This study aimed to investigate the unique genomic, transcriptomic, and immune landscapes of metastatic ILC using a multi-omic approach. Methods: This real-world study included patients with confirmed NST or pure ILC who had a biopsy of a metastatic lesion or a breast lesion in the setting of known metastatic disease. Tumors underwent whole exome sequencing (NGS 592, NextSeq; WES, NovaSeq), whole transcriptome sequencing (WTS, NovaSeq) (Caris Life Sciences, Phoenix, AZ). Demographic and baseline molecular features were compared across histologic subtypes. Tumor mutational burden (TMB; high ≥10 mut/MB) was assessed by NGS. Immune cell populations were estimated by RNAseq deconvolution (quanTIseq). Pathway enrichment analysis was determined by GSEA. Overall survival (OS) was defined from the date of biopsy to death from any cause using Kaplan-Meier estimates. Statistical tests included chi-square and Mann-Whitney U with multiple testing correction (q&lt;0.05). Results: Among 2,651 metastatic BC samples (ILC n = 608; NST n = 2,043), patients with ILC were older (median 67 vs 63 yrs) and more likely white (81.5% ILC vs 73.1% NST), all p&lt;0.05. By IHC, ILC were more frequently HR+/HER2- (83.6% vs 55.9%), less commonly triple-negative (11.9% vs 29.8%) or HER2+ (4.6% vs 14.3%), all p&lt;0.05. PAM50 subtypes differed between ILC and NST: luminal A (Lum A) (31.1% vs 13.7%) and luminal B (Lum B) (44.9% vs 43.8%) intrinsic subtypes were enriched in ILC, while NST was more frequently basal (1.2% vs 22.4%) and HER2-enriched (19.8% vs 22.2%), all p&lt;0.05. Within luminal BC, Lum B was more common than Lum A in both histologies, but Lum A was proportionally more frequent in ILC (ILC: 40.3% Lum A vs 59.7% Lum B; NST: 23.4% Lum A vs 76.6% Lum B), p&lt;0.0001. Comparative multi-omic analysis focused on the 922 HR+/HER2- tumors (ILC n = 275; NST n = 647). Compared to NST, ILC had higher frequency of CDH1 (87.3% vs 6.1%), PIK3CA (52.7% vs 38.5%), FOXA1 (9.0% vs 3.4%), ERBB2 (7.1% vs 2.0%), ARID1A, and NF1 (both q &lt; 0.05) mutations and TMB high (17.7% vs 9.9%), but lower frequency of TP53 (15.7% vs 33.3%), ESR1 (10.9% vs 18.1%) and GATA3 (2.3% vs 14.9%) mutations along with FGFR1 amplifications (15.3% vs 6.7%), all q&lt;0.05. ILC had higher expression of androgen receptor (91.2% vs 83.5%, q&lt;0.05) and higher MAPK activation score (-0.81 vs -1.19, q&lt;0.05), consistent with a luminal, hormone-driven phenotype. NST tumors demonstrated enrichment of pathways involved in the cell cycle and metabolic activity, including E2F targets, G2M checkpoint, MYC targets, mTORC1 signaling, glycolysis, and unfolded protein response (NES: 1.5-2.7, FDR&lt;0.25). ILC tumors had higher infiltration of B cells, dendritic cells, neutrophils, NK cells and M2 macrophages, but lower M1 macrophages, all q&lt;0.05. ILC had differential expression of immune checkpoint genes (upregulation: CD274 (PD-L1), PDCD1 (PD-1), TNFSF14, CEACAM1, CD160, fold change (FC): 1.2-1.5; down: HAVCR2 (TIM-3): FC: 1.2), all q&lt;0.05. Median OS (mOS) was similar between luminal ILC and NST (33.8 vs 35.4 months (mo); HR 1.0, 95% CI 0.91-1.3). No mOS difference was seen between Lum A ILC and NST (47.4 vs 50.5 mo; HR 1.0, 0.84-1.43), while Lum B ILC had worse mOS than NST (27.4 vs 35.3 mo; HR 1.3, 1.1-1.6). Conclusions: This study represents the largest cohort to date with multi-omic characterization of metastatic ILC, revealing distinct genomic, transcriptomic, and immune features compared to NST. These findings highlight the unique biology of ILC and may inform future subtype-specific therapeutic strategies. Citation Format: G. Nader-Marta, S. Kumar Deshmukh, K. Fanucci, P. Tarantino, S. Schnitt, A. Lee, S. Oesterreich, S. Wu, J. Xiu, P. Advani, M. Lustberg, N. Lin, S. Tolaney, E. Mayer, O. Metzger, G. Sledge Jr., R. Jeselsohn. The Genomic, Transcriptomic, and Immune Hallmarks of Metastatic Lobular Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD9-07.
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Leone, José Pablo , Ruddy, Kathryn J. , Rashid, Naim U. , Ortiz-Perez, Tamara, Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Krop, Ian E. , Thompson, Alastair M. , Sukumar, Jasmine S , Giordano, Sharon H. , Gupta, Gaorav P , Hilsenbeck, Susan Galloway , Walsh, Elaine M. , Makhlin, Igor , Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Spanheimer, Philip M. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS632-TPS632

10.1200/jco.2024.42.16_suppl.tps632 Get It

TPS632 Background: Male breast cancer is a rare disease, and most cases are hormone receptor-positive (HR+). Due to a lack of clinical trials, male breast cancer has historically been treated based on data extrapolated from women. However, there are substantial knowledge gaps in the comparative efficacy, safety, and patient-reported outcomes of endocrine therapies for male breast cancer. While tamoxifen is the current standard of care, additional data are warranted for aromatase inhibitors (AI), gonadal suppression, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Methods: This is an open-label, multicenter, randomized, phase II trial designed to evaluate different endocrine therapies in men with HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A total of 60 men will be enrolled across nine (9) sites within the Translational Breast Cancer Research Consortium (TBCRC). Key eligibility criteria include male sex and stage I, II, or III HR+/HER2- breast cancer before surgical resection of the primary tumor and axillary nodes. Key exclusion criteria include prior anti-cancer therapy for the current breast cancer or any other malignancy within the past 12 months, and inflammatory breast cancer. The trial has two phases. The first phase is a window of opportunity component in which newly diagnosed men are randomized 1:1:1 to either tamoxifen (Arm A), anastrozole (Arm B), or anastrozole plus degarelix (Arm C) given for three weeks. The primary endpoint for the window phase is Ki-67 reduction from the baseline diagnostic biopsy to the research biopsy at the end of the window phase. The second phase consists of neoadjuvant treatment, in which the tamoxifen group is randomized 1:1 to tamoxifen (Arm D) versus tamoxifen plus abemaciclib (Arm E), and the anastrozole alone (Arm B) and anastrozole plus degarelix (Arm C) groups are merged and then randomized 1:1 to anastrozole plus degarelix (Arm F) versus anastrozole plus degarelix plus abemaciclib (Arm G). The duration of the neoadjuvant phase is four (4) months, and the primary endpoint of this phase is residual cancer burden (RCB) index at time of surgery. The trial is powered for the RCB endpoint in a 2 x 2 factorial design to detect a 0.6 unit decrease in RCB index with 80% power and alpha=10%. For the Ki-67 endpoint, we assume an approximately 50% reduction in Arms A and B; Arm C will be of interest if it leads to ≥80% reduction in Ki-67. Secondary endpoints include: estradiol and testosterone levels at baseline, end of window, and during neoadjuvant phase; preoperative endocrine prognostic index (PEPI) score at surgery; adverse events; and patient-reported outcomes (including quality of life). Tumor tissue will be collected for correlative analyses. The study opened to enrollment at Dana-Farber in October 2023, and additional sites will open in 2024. Clinical trial information: NCT05501704 .
Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition
Lo, Yungtai , Lester, Susan C. , Lanjewar, Sonali, Laurini, Javier A., Patel, Ami , Bhattarai, Ava, Ustun, Berrin , Harmon, Bryan, Kleer, Celina G. , Ross, Dara S. , Amin, Ali , Wang, Yihong , Bradley, Robert, Turashvili, Gulisa , Zeng, Jennifer , Baum, Jordan , Hakima, Laleh , Harigopal, Malini, Shin, Sandra J. , Abbott, Sara, Jaffer, Shabnam , Badve, Sunil Shankar, Khoury, Thaer , D’Alfonso, Timothy M. , Collins, Victoria , Towne, William S. , Gan, Yujun, Flieder, Andrea, Aldrees, Rana, Ngo, Marie-Hélène , Edema, Ukuemi, Sapna, Fnu , Schnitt, Stuart J. , Fineberg, Susan , Komforti, Miglena, Wang, Yihong , Turashvili, Gulisa , Ellis, Ian O. , Singh, Kamaljeet , Komforti, Miglena K. , Badve, Sunil , Ginter, Paula S. , Nassar, Aziza , Şahin, Ayşegül A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 20, 2024 | Volume: 148 | Issue: 10 | Pages: 1119-1125

10.5858/arpa.2023-0163-oa | PMID 38244086 Get It

Context.— The Nottingham Grading System (NGS) developed by Elston and Ellis is used to grade invasive breast cancer (IBC). Glandular (acinar)/tubule formation is a component of NGS. Objective.— To investigate the ability of pathologists to identify individual structures that should be classified as glandular (acinar)/tubule formation. Design.— A total of 58 hematoxylin-eosin photographic images of IBC with 1 structure circled were classified as tubules (41 cases) or nontubules (17 cases) by Professor Ellis. Images were sent as a PowerPoint (Microsoft) file to breast pathologists, who were provided with the World Health Organization definition of a tubule and asked to determine if a circled structure represented a tubule. Results.— Among 35 pathologists, the κ statistic for assessing agreement in evaluating the 58 images was 0.324 (95% CI, 0.314–0.335). The median concordance rate between a participating pathologist and Professor Ellis was 94.1% for evaluating 17 nontubule cases and 53.7% for 41 tubule cases. A total of 41% of the tubule cases were classified correctly by less than 50% of pathologists. Structures classified as tubules by Professor Ellis but often not recognized as tubules by pathologists included glands with complex architecture, mucinous carcinoma, and the “inverted tubule” pattern of micropapillary carcinoma. A total of 80% of participants reported that they did not have clarity on what represented a tubule. Conclusions.— We identified structures that should be included as tubules but that were not readily identified by pathologists. Greater concordance for identification of tubules might be obtained by providing more detailed images and descriptions of the types of structures included as tubules.
Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers
Katopodi, Xanthi Lida, Kalavros, Nikolaos , Tran, Antuan V. , Karagkouni, Dimitra , Stern-Gatof, Emily, Schnitt, Stuart J. , Vlachos, Ioannis S. , Tung, Nadine, Vlachos, Ioannis S , Batalini, Felipe , Gulhan, D. , Katopodi, Xanthi-Lida , Garber, Judy E. , Wulf, Gerburg M. , Park, Peter J. , Tung, Nadine

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: P5-12-03-P5-12-03

10.1158/1538-7445.sabcs22-p5-12-03 Get It

Abstract Background Breast cancers in women with a germline BRCA1/2 mutation (gBRCAm) have homologous recombination deficiency (HRD) and are sensitive to therapies causing double-strand DNA breaks. In TBCRC 031 (INFORM), both neoadjuvant cisplatin and doxorubicin/cyclophosphamide (“AC”) in gBRCAm carriers resulted in a complete pathologic response in 18% and 26% respectively in patients with newly diagnosed HER2–negative breast cancer. Herein, we describe molecular features from tumor whole exome (WES) and transcriptome sequencing (RNAseq) associated with response. Methods TBCRC 031 (the INFORM Trial - NCT01670500) was a randomized phase II neoadjuvant trial comparing the efficacy of cisplatin versus AC in gBRCAm carriers with stage I-III HER2–negative breast cancer. Of 118 patients enrolled, 92 patients provided fresh frozen research biopsies, collected prior to chemotherapy initiation, which were subjected to WES and RNAseq. Variants were called using GATK best practices and intratumoral heterogeneity was inferred from mutations and variant allele frequencies using Mutant Allele Tumor Heterogeneity (MATH) scores. Mutational Signature 3 (Sig3) and Genomic Instability Score (GIS) were calculated with SigMA and scarHRD, respectively. RNAseq data were utilized to perform differential gene expression and functional analyses, while cellular deconvolution was performed with CIBERSORTx trained against breast cancer single cell data. Patients were grouped according to their residual cancer burden (RCB) as responders (RCB-0 or 1), or non-responders (RCB-2 or 3). P-values ≤ 0.05 were considered statistically significant and when appropriate, adjustment for multiple testing was performed using a false discovery rate ≤ 5%. Results Of the 92 patients with gBRCAm, 59 (64%) had triple-negative and 33 (36%) were hormone-receptor positive HER2-negative breast cancer, 40 (43%) were classified as responders and 52 (57%) as non-responders. WES analysis revealed that indices of HRD were high (Sig3 exposure predominant and GIS ≥ 42) across most samples irrespective of receptor status and not significantly different among responders and non-responders. In contrast, responders exhibited lower levels of intratumor heterogeneity than non-responders (median MATH 42.9 vs. 33.5, p = 0.01). 223 genes were differentially expressed between responders and non-responders following control for tumor hormone receptor status, BRCA1/2 mutation, and menopausal status. Pathways identified as significantly enriched in upregulated genes were indicative of intrinsic immune activation in responders (e.g., T-cell activation, immune response-signaling, and regulation of leukocyte activation). Cellular deconvolution of the tumor microenvironment confirmed that responders presented a higher proportion of T-cells (p = 0.025) and myeloid cells (p = 0.003) in the tumor samples, while perivascular-like cells were enriched in non-responders (p = 0.034). Conclusion In this analysis of the largest cohort of treatment-naïve gBRCAm breast cancer to date, we found that response to cytotoxic chemotherapy is associated with a transcriptional program of intrinsic immune activation and an increased population of intratumoral T-cells and myeloid cells. Lower levels of intratumor heterogeneity and higher immune activation were associated with response to chemotherapy gBRCAm carriers while HRD scores were not. Citation Format: Felipe Batalini, Doga C. Gulhan, Xanthi Lida Katopodi, Nikolas Kalavros, Antuan Tran, Dimitra Karagkouni, Emily Stern-Gatof, Stuart Schnitt, Judy E. Garber, Gerburg M. Wulf, Peter J. Park, Ioannis Vlachos, Nadine Tung. Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-12-03.
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
González-Ericsson, Paula I. , Stovgaard, Elisabeth Specht , Reisenbichler, Emily , Kos, Zuzana , Carter, Jodi M. , Michiels, Stefan , Quesne, John Le , Lænkholm, Anne‐Vibeke , Adam, Julien , Bartlett, John MS, Rimm, David L. , Quinn, Cecily , Cree, Ian A. , Hida, Akira I. , Haynes, Harry R. , Frahm, Isabel, Acosta‐Haab, Gabriela, Balancin, Marcelo Luiz , Bellolio, Enrique , Yang, Wentao , Kirtani, Pawan , Sugie, Tomoharu , Ehinger, Anna , Castaneda, Carlos, Kok, Marleen , McArthur, Heather L. , Siziopikou, Kalliopi P. , Fineberg, Susan , Gown, Allen M. , Viale, Giuseppe , Schnitt, Stuart J. , Pruneri, Giancarlo , Penault‐Llorca, Frederique, Hewitt, Stephen M. , Thompson, E. Aubrey , Allison, Kimberly H. , Symmans, W. Fraser , Bellizzi, Andrew M. , Brogi, Edi , Moore, David A. , Larsimont, Denis , Dillon, Deborah , Broeckx, Glenn , Bairi, Khalid El , Cimino‐Mathews, Ashley , Adams, Sylvia , Liu, S, Loibl, Sibylle , Chen, I‐Chun , Juco, Jonathan, Blackley, Elizabeth F. , Demaria, Sandra , Leon‐Ferre, Roberto A. , Zardavas, Dimitrios, Emancipator, Kenneth , Ely, Scott , Loi, Sherene , Salgado, Roberto , Group, International Immuno‐Oncology Biomarker Working, Cree, Ian , Haynes, Harry R , Balancin, Marcelo , Ehinger, Anna , Lazar, Alexander J , Broeckx, Glenn , El Bairi, Khalid , Leon-Ferre, Roberto, Gonzalez-Ericsson, Paula I , Bellizzi, Andrew M , Symmans, W Fraser , Loi, Sherene , Pruneri, Giancarlo , Rimm, David , Carter, Jodi , Sua, Luz Fernanda , Nielsen, Torsten O. , Fox, Stephen B. , Bartlett, John MS, Peeters, Dieter J. E. , Dieci, Maria Vittoria , Vincent‐Salomon, Anne , Balko, Justin M. , Badve, Sunil , Penault-Llorca, Frederique Madeleine , Lazar, Alexander J. , Lien, Huang‐Chun , Goetz, Matthew P. , Harbeck, Nadia , Sotiriou, Christos P. , Lakhani, Sunil R. , Denkert, Carsten , Gluz, Oleg , Sanders, Melinda E. , Group, International Immuno‐Oncology Biomarker Working

Mayo Clinic

The Journal of Pathology | March 4, 2020 | Volume: 250 | Issue: 5 | Pages: 667-684

10.1002/path.5406 | PMID 32129476 Get It

AbstractImmune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.